AI Article Synopsis
Article Abstract
Objective: To study clinical effects of preoperative intra-internal iliac-arterial chemotherapy for invasive bladder cancer.
Methods: 14 cases of invasive bladder cancer underwent superselective intra-internal iliac-arterial chemotherapy before conservative cystectomy.
Results: After 2-3 week therapy, reduction of cancer volume (20%-50%), clotted by thrombus in the blood vessels of the cancer or circumferential tissue, and decreased bleeding were found. Pathomorphological features included large patchy necrosis, degeneration, and inflammatory changes of carcinoma tissue. Follow-up ranged from 5 to 42 months (mean 19.6 months). One T3 N1 M0) of the cases (0.7%) relapsed into T1N0M0 and the others did not.
Conclusions: The intra-internal iliac-arterial method, simple, safe, coordinates in pre-operation for invasive bladder cancer, and increases the operative opportunity for preservation of functional bladder.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
The combination treatment of RC48 and STAT3 inhibitor acts as a promising therapeutic strategy for basal bladder cancer.
Front Immunol
January 2025
Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China.
As an antibody-drug conjugate (ADC), disitamab vedotin (RC48) is a promising treatment targeting ERBB2 for locally advanced and metastatic bladder cancer (BLCA). However, the subtype heterogeneity of muscle-invasive bladder cancer (MIBC) often leads to different therapeutic outcomes. In our study, we aim to explore sensitivity differences and mechanisms of different molecular subtypes of MIBC to RC48 treatment and develop a strategy for combination therapy against cancer.
View Article and Find Full Text PDFAI predicting recurrence in non-muscle-invasive bladder cancer: systematic review with study strengths and weaknesses.
Front Oncol
January 2025
School of Engineering, Newcastle University, Newcastle Upon Tyne, United Kingdom.
Background: Non-muscle-invasive Bladder Cancer (NMIBC) is notorious for its high recurrence rate of 70-80%, imposing a significant human burden and making it one of the costliest cancers to manage. Current prediction tools for NMIBC recurrence rely on scoring systems that often overestimate risk and lack accuracy. Machine learning (ML) and artificial intelligence (AI) are transforming oncological urology by leveraging molecular and clinical data to enhance predictive precision.
View Article and Find Full Text PDFImpact of race-based calculations of eGFR on the management of muscle invasive bladder cancer.
Am J Clin Exp Urol
December 2024
Division of Urology, Department of Surgery, School of Medicine, University of Maryland Baltimore, MD, USA.
Purpose: The estimated glomerular filtration rate (eGFR) has historically been calculated with a race-coefficient multiplier (RCM); however, the RCM has been broadly criticized as inaccurate and a potential contributor to exacerbating disparities. We evaluated the impact of the RCM on eGFR and examined the 30-day post-cystectomy complications in a muscle-invasive bladder cancer cohort.
Materials And Methods: We retrospectively analyzed patients diagnosed with MIBC who underwent cystectomy in the ACS NSQIP database from 2006 to 2020 using CPT and ICD codes.
First full intracorporeal robotic cystectomy and neobladder in a renal transplant recipient.
J Surg Case Rep
January 2025
UNICAEN, Urology and Transplantation Department, Normandie University, CHU de Caen, Avenue de la Côte de Nacre, Caen 14000, France.
The literature regarding robotic-assisted radical cystectomy in kidney transplant recipients is limited. We present the first reported case of robotic-assisted radical cystectomy with a full intracorporeal orthotopic neobladder in a kidney transplant recipient. A 36-year-old man was diagnosed with muscle-invasive urothelial carcinoma 12 years after kidney transplantation.
View Article and Find Full Text PDFEn bloc resection of large bladder tumor: is it feasible and reasonable?
Curr Opin Urol
January 2025
Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.
Purpose Of Review: Transurethral resection of bladder tumor (TURBT) remains the basis of bladder tumor diagnosis and an effective means of treating nonmuscle invasive bladder cancer (NMIBC). There are several limitations to this procedure: TURBT may cause free floating of malignant cells in the bladder and as a result re-implantation and early recurrence. Also, it does not allow the pathologist to define the correct spatial orientation of the specimen.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!